The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

AstraZeneca has secured a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

Furthermore, myasthenia gravis can also affect the bulbar muscles, leading to difficulties in swallowing, chewing, speaking, and breathing, says Mehta. With Rystiggo, Significant Improvements.